The combination also provides silymarin's antioxidant activity, creating a comprehensive metabolic support formula that supports both glucose metabolism and healthy oxidative balance
Despite the early termination of the trial, it is interesting to note that 13 of 140 patients had a median duration of response of 10.2 months, indicating that these patients benefited from combination therapy and that exploring the mechanisms of this benefit should be the focus of future research
doi: 10.1002/hep4.1209 73 KilanczykEBanalesJMWunschEBarbierOAvilaMAMatoJMet al
After this period, your provider may recommend: A 1-2 month break before resuming Continued treatment with periodic monitoring Dose adjustments based on your response Long-term use beyond 6 months should include periodic lab testing (IGF-1 levels, metabolic panel) and provider evaluation
If your GLP-1 side effects are hitting hard, the session adapts
The transaldolase reaction involves Schiff base formation between the substrate and a lysine residue in the enzyme
